Brisbane Cancer Conference
Thursday, 23 November – Friday 24 November 2017
Brisbane Convention and Exhibition Centre

CONFERENCE HANDBOOK
Brisbane Cancer Conference Program, 23-24<sup>th</sup> November 2017
Brisbane Convention and Exhibition Centre
23<sup>rd</sup>-24<sup>th</sup> November, 2017

23<sup>rd</sup> November 2017
Thursday Morning Symposia

**Breast cancer symposium (supported by Roche) - Boulevard Room**
Chairs: Nicola Lowrey; Fiona Simpson
8.00am - Presenting your work to consumers – Fran Boyle
8.30am - Bioinformatic and functional evaluation of rare variants in the 5’ region of cancer susceptibility genes – Les Burke
8.48am - Causes and consequences of WDHD1 overexpression in breast cancer - Pacal Dujiff
9.06am - Diet, exercise & weight management in early-stage and metastatic breast cancer’ Marina Reeves
9.24am - Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials - Liz Eakin
9.42am - Targets and directions in breast cancer clinical trials - Cath Shannon

‘Morning tea’
10:30-12:00: Translational Breast Cancer Research in Australia
Chair: Rik Thompson
10.30am - Exploring new therapies for breast cancer brain metastasis in clinically-relevant syngeneic models - Normand Pouliot
11.10am - Metastatic breast cancer: changing clinical paradigms - Fran Boyle
11.50am - Discussion - Translational questions/approaches in Metastatic Breast Cancer - Rik Thompson

**Prostate cancer (supported by Astellas) – B1 and 2**
Chair: Colleen Nelson

*Adaptive response*
8.00am - Targeting the adaptive tumour plasticity response to androgen targeted therapies - Brett Hollier
8.30am - Understanding the Temporal Dynamics of EMT in prostate cancer a Network-Based Approach - Ati Taherian Fard
8.45am - Macrophage contributions to metastatic prostate cancer impacts on the bone microenvironment - Allison Pettit
9.00am - Inhibition of Neuropilin-1 as a novel adjuvant therapy in advanced prostate cancer - Marianna Volpert
9.15am - Involvement of the kallikrein-related peptidase 14 in aggressiveness of pro state cancer cells - Thomas Kryza
9.30am - The lncRNA GHSROS mediates tumour growth and expression of genes associated with metastasis a - Patrick Thomas
9.45am - The long and short of a GWAS identified long noncoding RNA - Jysotna Batra

‘Morning tea’
10:30am - Targeting glutamine metabolism in prostate cancer – Jeff Holst
10.45am - Co-targeting metabolic dysfunction and tumour growth in a hyperinsulinaemic mouse model of prostate cancer - Penny Jeffery
11.00am - Cholesterol, lipid raft and exosomal miRNA in prostate cancer - Michelle Hill
11:15am - Targeting leptin in prostate cancer - Lisa Philp  
11.30am - Targeting genetic instability in prostate cancer – Derek Richard  
11.45am - Targeting lipid metabolism in prostate cancer: New therapeutic concepts with old drugs - Rohan Davis

**Immuno-oncology (supported by AstraZeneca) – B3**  
Chair: Jeremy Long; Riccardo Dolcetti  
8.00 am - Immunobiology – Tobias Bald  
8.30 am - Immunogenomics - Lutz Krause  
8.50 am – Imaging in Immunotherapy – Kenneth Miles  
9.15 am – Immunotherapy challenges: rare tumours – David Thomas  
9.45 am – Breakthrough in breast cancer? Nicole McCarthy

‘Morning tea’  
10.30am – Immune checkpoint therapies and resistance mechanisms in haematological malignancies – Maher Gandhi  
10.50am – Immunotherapy plus radiotherapy: the Abscopal effect – Renee Finnigan  
11.10am – Novel immune checkpoint inhibitors - Michelle Wykes  
11.30am - CAR-T cell therapies - Michael Brown

**12.00pm – Tea and Coffee**

**Lunch-time symposium (supported by MSD) – Boulevard room**  
Chair: Rajiv Khanna  
12.30pm - Biomarkers in Immuno-oncology; now and the future - Caroline Cooper  
1.00pm - Lessons learnt in the immunotherapy of malignant disease - Ken O’Byrne

**Plenary Thursday pm – Boulevard Auditorium**  
Chairs: Robert Bowen; John Prins  

**Session 1**  
2.00pm - BDHP and cancer – Euan Walpole  
2.20pm - QGHA: where we are and where we are going –David Bunker  
2.40pm QGHA and Queensland pathology - Sunil Lahkani

**Session 2**  
Chairs: Janet Hardy; Michael Kimlin  
3.00pm - Palliative medicine – Will Cairns  
3.20pm - Stereotactic radiosurgery – Ben Chua  
3.40pm - Prevention of melanoma and skin cancer - David Whiteman

**4.00pm – Tea and Coffee**

**Thursday Workshops**  
**Imaging:**  
Chairs: Liz Kenny; Tom Lloyd – A1  
Imaging to guide therapy into the future  
4.30pm - MRI imaging in rectal cancer - Sonja Gustafson  
4.50pm - HERF cancer imaging program - Paul Thomas  
5.05pm - Theranostics program for CRISO - Simon Puttick  
5.20pm - LiRADS Managing Hepatocellular Imaging – Dave Leggett  
5.35pm - Breast imaging - Karin Steinke
5.55pm - PSMA-PET-MR – Kenneth Miles
Discussion

Genomics:
Chair: John Pearson – A2
4.30pm - is Artificial Intelligence and Machine Learning (AI/ML) and how can it help genomics? - Nicholas Therkelsen-Terry
4.50pm - What is cloud and how can it help genomics? - Steve Nicoll
5.10pm - The Australian Genomics ICCon Flagship - Managing Patient Risk: Hereditary Cancer Syndromes - Uwe Dressel
5.30pm - The Mesothelioma Genomics Project (MesoGen) - Ann-Marie Patch
5.50pm - Evaluating the economics of clinical genomics - Lousia Gordon

Clinical trials – B1
Chairs: Adam Stoneley; Suzanne Elliott
Theme: Developments on the doorstep
4.30pm – Introduction – Adam Stoneley
4.35pm – Bringing trials to remote locations – Sabe Sabesan
4.55pm – Implementation of HREA – Melissa Hagan
5.15pm – ICH GCP E6 R2 updates workshop – Sophie Mepham
6.00pm – The truth about RBM – Elizabeth Wilson
6.20pm – Discussion Panel & Questions – Suzanne Elliott

Commercialisation – B2
Chairs: Derek Richard; Mario Pennisi
4.30pm - Framework to coordinating interactions with international partners – Fares Al-Ejah
4.45pm - Nematode diagnostic tests, Hirotu Bio-Science Inc - Takaaki Hirotu
4.55pm - CARP Pharmaceuticals – Derek Richard
5.10pm - First steps into commercialization a salivary diagnostic test: collaboration with MDxHealth – Chaminde Punyadeera
5.20pm - Xing – Paul Mainwaring
5.35pm - Admedus – Neil Finlayson
5.50pm - Engaging Foundations – John Fraser
6.05pm - The industry perspective: Question and answer session – Alan Paul, Astrazeneca, Ian Black, Roche and MSD Pharma Partner representatives
6.20pm – Discussion

Palliative Medicine - B3
Chairs: Phillip Goode; Patsy Yeates
4.30pm - Identifying risk of deteriorating and dying in people with haematological malignancy - Elise Button
4.45pm - Methadone - what we have learnt from our PK studies - Rani George/Alison Haywood
5.00pm - Does dexamethasone improve dyspnoea? - a Cochrane review - Jacque Duc
5.15pm - Use of holistic needs assessment tool for hospice care of children at Hummingbird House - Ross Pinkerton
5.30pm - Research in medicinal cannabis - pitfalls and pearls - Phillip Good
5.45pm - Laughter and tears in interprofessional cancer care - Rebecca Olson
6.00pm – Discussion
7.00pm ‘til late – Gala Dinner

24th November 2017
Plenary Friday am – Boulevard Auditorium
Chairs: Robin Mortimer; Ian Irving
8.00am - Personalised medicine in lung cancer – Margie McGrath
8.15am - Clinical Leadership in Translational Research – Lewis Perrin
8.45am - Resection of liver metastases – Tom O’Rourke
9.00am - Theraonotics for NETs tumours – David Wyld
9.15am - New avenues in immunotherapy – Riccardo Dolcetti
9.30am - Translational research in prostate cancer - Colleen Nelson
9.45am - The role of patient derived xenografts in cancer research – Elizabeth Williams

10.00am – Tea and Coffee

Friday am workshops
Brain tumours - A1
Chairs: Mark Pinkham
10.30am - Investigating the HER2-3 dimer as a theranostic target in brain metastases - Jodi Saunus
10.45am - Role of systemic therapy in non-small cell lung cancer brain metastases – Robert Mason
11.00am - Radiological kinetics of brain metastases and clinical implications - Luke Nicholls
11.15am - Advances in radiosurgery for brain metastases - David Schlect
11.30am - Role of the Cancer Care Co-ordinator in the management of patients with brain metastases - Angela McBean
11.45am - Discussion

Novel Immunotherapies - A2
Chair: Rajiv Khanna
10.30am - Solid tumour immunotherapy – Bill Dougall
10.43am - Brain cancer immunotherapy – David Walker
10.56am - T-cell therapy - Siok Tey
11.10am - Dendritic cell vaccines – Kristen Radford
11.25am – A nanoparticulate cancer vaccine targeting cross-presenting dendritic cells – Ranjeny Thomas
11.40am - Cytokine release assay: From toxicity to response – Antiopi Varelius
11.50am - Discussion

Thoracic Malignancies - B1
Chairs: Henry Marshall; Simon Bowler
10.30am - Targeting therapy in thoracic oncology; tissue remains the issue – Suzanne Allan
10.38am - Optimising tissue collection for oncogene assessment – Michelle Murphy
10.46am - The role of the radiologist in tissue collection – Duncan Walker
10.54am - Pathology today and tomorrow – Cameron Snell
11.02am - Whole genome sequencing – Matt Brown
11.10am - CTCs – Arutha Kulasinghe
11.18am - ‘Lab-in-a-drop’ – Matt Trau
11.28am - ctDNA – Glenn Francis
11.36am - Proteins in exosomes - Andreas Moller
11.44am - Familial lung cancer – Emma Duncan
11.52am – Discussion

**Survivorship B2**
Chairs: Ray Chan; David Wyld
10.30am - Survivorship Interventions for Men with Prostate Cancer: Outcomes from the TrueNTH Pilot Study – Patsy Yates
10.50am - Cancer on the Margins: Experiences of Living with Neuroendocrine Tumours - David Wyld
11.10am - Healthy Living After Cancer Program – Liz Eakin
11.30am - Financial Toxicity in Cancer Survivors - Louisa Gordon
11.50am - Discussion

**GU malignancies – B3**
Chairs: Ian Vela; Jeff Goh
10.30am - Lu-PSMA/ Theranostics in metastatic CRPC – David Pattison
10.50am - Update on management of advanced urothelial/ bladder cancers – Aneta Suder
11.10am - Update on the management of advanced RCC – Jeff Goh
11.30am - Novel biomarkers in Renal Cell Cancer - Glenda Gobe
11.50am - Discussion

**Gynae-oncology – Boulevard room**
Chair: Lewis Perrin; Pam Pollock; Monika Janda
10.30am - Opening Remarks – Pam Pollock
10.33am - Update of Immunology and Cervical Cancer Vaccines – Janin Chandra
10.57am - MRI Spectroscopy and Diagnosis of Ovarian Cancer - Peter Malycha
11.09am - Inhibition of Epigenetic Modifying Enzymes: A Preclinical Model for Ovarian Cancer - Jason Lee
11.21am - Sentinel Node Biopsy and Endometrial Cancer - Nisha Jagasia
11.33am - Intraepithelial Endometrial Cancer - Andreas Obermair
11.45am - Genomic Changes in Gestational Trophoblastic Disease - Andrea Garrett
11.57am - Closing Remarks - Monika Janda

**Pharmacy – Boulevard auditorium**
Chair: Dan McKavanagh; Emily Wenta
Topic: Brisbane Cancer Pharmacy – Service Snapshots
Cancer Pharmacy in Queensland is at the cutting edge of service delivery, with many pharmacies providing expert care in large clinics, using innovative systems, and managing complicated clinical presentations. This session will provide a snapshot from some of these pharmacies and a great opportunity to share innovative models of practice
10.30am - The 2017 COSA Guidelines – an update for cancer pharmacists – Christine Carrington
10.45am - Princess Alexandra Hospital - Kate Ross
11.00am - Icon Cancer Care
   o Wesley Hospital/Regional - Jodie Lyons
   o South Brisbane - Braedon Denham
11.30am - Royal Brisbane & Women’s Hospital - Paul Klages
11.45am – Discussion

12.00pm – Tea and Coffee

Plenary Friday lunch-time – Boulevard auditorium
Chairs: Frank Gannon & Stephen Ayre
12.30pm - Genomics and bioinformatics: now and the future – Nic Waddell
12.50am - Melanoma and the immune revolution in cancer care – Victoria Atkinson
1.10pm - Personalised medicine in haematology – Geoff Hill
1.30pm - Overview of cancer Survivorship Research in Queensland – Ray Chan

2.00pm – Tea and Coffee

Small 3D cancer models - A1
Chair: Laura Bray; Jacqui McGovern
2:30-2:32 Overview of the agenda, goals for the day. Laura Bray
2:32-3:15 3D in vitro cancer models
   1. Real-time cell cycle imaging in a 3D cell culture models of melanoma - Loredana Spoerri
   2. Hydrogels for 3D cell culture and cancer models - Christoph Meinert
   3. Developing a bioengineered 3D model to study the role of bone marrow adipocytes in prostate cancer bone metastasis - Joan Röhl
   4. Microscopy techniques for cancer imaging – Sandrine Roy
3:15-4:00 3D in vivo cancer models
   1. Studying mitotic and chromosome segregation defects in in vitro and in vivo 3D cancer models - Pascal Duiff
   2. Animal model to study immune regulation of prostate cancer tumour bone microenvironment - Andy Wu
   3. Humanised mouse models to evaluate new cancer immunotherapies - Oscar Haigh
   4. Tissue-engineering an in vivo humanized bone model for cancer applications - Jacqui McGovern

Breast cancer - A2
Chairs: Katharine Cuff, Fiona Simpson, Juliet French, Nicola Lowrey, Rik Thompson
2.30pm - The genomic landscape of familial breast cancer – Pete Simpson
2.50pm - Synergistic radiotherapy treatment with immunotherapeutic agents for triple negative breast cancer - Preliminary preclinical results - Davide Fontanarosa
3.10pm - Oncogenic transposon activation in breast cancer - Kyle Upton
3.30pm - Some new nanotechnologies for personalising cancer diagnostic - Matt Trau
3.50pm - Discussion – Optimising breast cancer research in Brisbane

Melanoma and skin cancer - B1
Chairs: Peter Soyer; Nikolas Haass
2.30pm - Duality of proliferative behaviour in the interfollicular epidermis upon chronic UV irradiation: implications for carcinogenesis - Edwige Roy
2.40pm - Translating melanoma genomic data using high-content imaging of melanocyte-keratinocyte interaction - Dubravka Škalamera
2.50pm - Melanoma-microRNAs as novel disease biomarkers - Mitchell Stark
3.00pm - BRN2-MITF phenotype switching in melanoma cells promotes invasion and
metabolic adaptation to micro-environmental cues - Yash Chhabra
3.10pm - NDRG1-mediated down-regulation of MITF drives dynamic heterogeneity in melanoma spheroids - Farzana Ahmed
3.20pm - Novel targets of BRN2 contributing to melanoma metastasis - Glen Boyle
3.30pm - PTEN mutant melanomas exhibit a drug-resistant cell state but are responsive to AKT inhibition - Ken Dutton-Regester
3.40pm - H3K4me3 remodeling drives escape from the BRAF inhibitor induced slow cycling phenotype - Heinz Hammerlindl
3.50pm - HGF/c-MET signalling a resistance mechanism to immunotherapy - Tobias Bald

**Head and neck cancer - B2**
Chairs: Rahul Ladwa; Chris Perry
2.30pm - Updates on systemic therapy in Head and Neck cancer – Brett Hughes
2.38pm - H-IMRT data from their respective fields - Laura Moroney & Claire Blake
2.46pm - The expanding role of trans-oro-robotic surgery (Pathos Trial) - Matthew Ward
2.54pm - Reconstruction post head and neck cancer surgery - Milap Rogani
3.02pm - Demographics of HPV associated oro-pharyngeal cancer – Anneke Antonsson
3.10pm - Discussion
3.20pm - New systemic trials
  - Stemetil proof of principle and current phase I trial - Fiona Simpson
  - EBC 46 lab work and phase 1 EBC 46 trial - Courtney Henrys
  - Phase II study on a therapeutic vaccine for HPV+ oropharyngeal cancer – Janin Chandra
3.32pm - Advances in vocal rehabilitation after laryngectomy - Bena Cartmill/Kelli Hancock
3.40pm - Liquid biopsies in Head and Neck cancer – Kai Tang
3.48pm - Discussion

**Haematology - B3**
Chair: Colm Keane; Stephan Lane
2.30pm - Improving GVL with Interferon post-allogeneic Bone Marrow Transplant - Andrea Henden
2.45pm - Update on Amyloidosis - Peter Mollee
3.00pm - The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in Acute Myeloid Leukaemia: a Randomized Trial in Patient-Derived Xenografts - Claudia Bruedigam
3.15pm - The Tumour Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma - Joshua Tobin
3.30pm - Update on BDHP clinical trials network for Haematology - Steven Lane
3.45pm - Discussion

**GI malignancies - Boulevard room**
Chair: Chris Gillespie; Vikram Jain
Theme: Identifying clinical research opportunities through audit and the laboratory
2.30pm - Fund raising for gastro-intestinal tract cancers in Brisbane – Damian Topp
2.40pm - Rectal cancer audit update – Vikram Jain & Chris Gillespie
2.50pm - Resection of colorectal metastases – the uncertainty principle – Andrew Robson
3.00pm - Discussion
3.10pm - Peritonectomy in Brisbane – Sanjeev Naidu
3.20pm - Neoadjuvant pancreatic cancer study – Warren Joubert
3.30pm - Integration of genomics into GI clinical trials – Felicity Newell
3.40pm - Targeting MUC13 to sensitise colorectal cancers to chemotherapy and immunotherapy - Yong Sheng
3.50pm – Discussion

**4.00pm – Tea and Coffee**

**Plenary Friday evening - Boulevard Auditorium**
Big data
Chairs: Michael Cleary; David Theile
4.10pm - Google Bio-informatics - TBC
4.25pm - IBM-Watson – Terry Sweeney
4.40pm - Queensland Health Road Map Big Data; Shaping Our Future - Richard Ashby
4.55pm – Discussion

5.15pm Wine and Cheese

**6.00pm Exit**